Notice of Annual General Meeting of Infant Bacterial Therapeutics
03 avr. 2023 05h20 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on May 8, 2023 at 15.00 CEST at Westmanska...
Infant Bacterial Therapeutics publicerar årsredovisning för 2022
22 mars 2023 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2022. Årsredovisningen finns tillgänglig på IBTs hemsida, www.ibtherapeutics.com under avsnittet...
Infant Bacterial Therapeutics publishes Annual Report for 2022
22 mars 2023 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022. The report is available on IBT´s website, ibtherapeutics.com under the section Ïnvestors & Media – Financial...
Infant Bacterial Therapeutics (IBT) öppnar en sista kohort vilket påskyndar rekryteringen av patienter
22 mars 2023 05h31 HE
|
Infant Bacterial Therapeutics AB
IBT är glada att kunna meddela dagens öppning av den ytterligare kohorten, efter att ha inkluderat 1400 för tidigt födda barn av det totala rekryteringsmålet på 2158. Fram tills nu, och i enlighet men...
Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment
22 mars 2023 05h31 HE
|
Infant Bacterial Therapeutics AB
IBT is pleased to announce today's opening of the additional cohort, having included 1,400 premature infants of the total 2,158 recruitment target. Up until now, and per the protocol agreed with...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
15 mars 2023 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product...
7MM CAEL-101 Market Study 2022: A Fibril-reactive Monoclonal Antibody (mAb) - Emerging Drug Insights and Market Forecasts 2019-2022 & 2023-2032
15 févr. 2023 07h53 HE
|
Research and Markets
Dublin, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The "CAEL-101 Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering."CAEL-101 Emerging Drug...
Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari – 31 december 2022
10 févr. 2023 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de sista tre månaderna av 2022 var rekryteringen av prematura spädbarn till vår omfattande fas 3 studie betydligt bättre än vad den var under motsvarande period de föregående...
Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022
10 févr. 2023 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of 2022 compared to the corresponding period in...
Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis
08 févr. 2023 09h00 HE
|
InSilico Medicine
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that...